Phaseline

Companies › Pacira Pharmaceuticals

Pacira Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 16 registered trials: 5 Phase 2, 5 Phase 4, 3 Phase 1, 3 Phase 3; Immunology, Other, Gastroenterology, Infectious disease; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Triamcinolone
Glucocorticoid receptor agonist
NR3C1Phase 3Glenohumeral Osteoarthritis; Pain; Osteoarthritis, Knee; Osteoarthritis of Knee …Dec 2026
Enekinragene Inzadenovec (PCRX-201)
Gene therapy encoding TNF receptor:Fc fusion protein
–Phase 2Osteoarthritis (OA) of the KneeNov 2026
FX201 (humantakinogene hadenovec)
interleukin-1 receptor antagonist (IL-1Ra) gene therapy
IL1RNPhase 1Osteoarthritis, KneeNov 2026
Bupivacaine
Sodium channel protein type IV alpha subunit blocker
Ion channelsPhase 1Postoperative PainJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06779396TriamcinolonePhase 4PainOtherMar 2025
NCT06729840TriamcinolonePhase 3Scar, HypertrophicImmunologyApr 2025
NCT06681688TriamcinolonePhase 1CataractOphthalmologyJun 2025
NCT07311759TriamcinolonePhase 3Chronic ParonychiaInfectious diseaseDec 2025
NCT06237153TriamcinolonePhase 2Carpometacarpal (CMC) OsteoarthritisImmunologyDec 2025
NCT06981767TriamcinolonePhase 2Oral Lichen PlanusGastroenterologyJul 2026
NCT06884865Enekinragene Inzadenovec (PCRX-201)Phase 2Osteoarthritis (OA) of the KneeImmunologyNov 2026
NCT04119687FX201 (humantakinogene hadenovec)Phase 1Osteoarthritis, KneeImmunologyNov 2026
NCT06269705TriamcinolonePhase 3Glenohumeral OsteoarthritisImmunologyDec 2026
NCT06478186TriamcinolonePhase 4Osteoarthritis, KneeImmunologyDec 2026
NCT06271265BupivacainePhase 1Postoperative PainOtherJan 2027
NCT06782529TriamcinolonePhase 4Osteoarthritis of KneeImmunologyJan 2027
NCT06782529TriamcinolonePhase 4Osteoarthritis of KneeImmunologyJan 2027
NCT07714525TriamcinolonePhase 2Chronic Rhinosinusitis (CRS)RespiratoryMay 2027
NCT04641351TriamcinolonePhase 4Osteoarthritis, KneeImmunologyAug 2027
NCT07151417TriamcinolonePhase 2Knee OsteoarthritisImmunologyAug 2027

From the company's SEC filings

Cash and short-term investments of $296m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

Ion channels (1) IL1RN (1) NR3C1 (1)

Companies with the same targets

Corcept Therapeutics Xenon Pharmaceuticals Praxis Precision Medicines Viatris HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics

Companies built like this

BioCryst Pharmaceuticals Arcutis Biotherapeutics Spyre Therapeutics Teva Branded Pharmaceutical Products R&D Mirador Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.